Investigating the Relationship Between Sleep, Quality of Life,Other Disorders and Therapies in MS Patients on Betaferon

• Status: Completed
• Trial end date: 2017-03-14
• Target enrollment: 0
• Participant gender: All

Summary

The study aims to investigate the relationship between sleep quality, quality of life,other disorders and therapies in Multiple Sclerosis (MS) patients treated with Betaferon.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bayer
• Treatments: Interferon beta-1b; Interferon-beta; Interferons

Criteria

Inclusion Criteria:

• Patients ≥ 18 years of age with relapsing remitting multiple sclerosis or a clinically isolated syndrome and an expanded disability status scale score ≤5.

• Patients must be on treatment with Betaferon and tolerate Betaferon according to the investigator's evaluation, but should not have received Betaferon longer than six months.

• Written informed consent must be obtained

Exclusion Criteria:

• Patients who do not tolerate Betaferon according to the investigator's evaluation or have been treated with Betaferon for more than six months.

• Patients receiving any other disease modifying drug or MS specific treatments

• Contraindications of Betaferon described in the Summary of Product Characteristics.